Infant Bacterial Therapeutics AB (publ)

Infant Bacterial Therapeutics AB (publ) is a biopharmaceutical company in the clinical development phase, specializing in creating treatments for serious and uncommon conditions that impact prematurely born infants. Based in Stockholm, Sweden, and established in 2013, the company's primary therapeutic candidate is IBP-9414, which aims to both prevent necrotizing enterocolitis (NEC) – a severe intestinal disease – and enhance digestive tolerance in these vulnerable newborns. Additionally, they are progressing IBP-1016, designed to address gastroschisis, a critical congenital defect affecting infants.